SCHEMBL3464161

SCHEMBL3464161

Cc1[nH]nc(C(C)(C)O)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.44
DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1120066 0.76 NR2F2 (0.41) HCAR2DYRK1A
SCHEMBL16800437 0.74 CDK8 (0.33) DYRK1A
SCHEMBL13683080 0.74 DYRK1A (0.31) DYRK1A
SCHEMBL1531052 0.67
SCHEMBL24687302 0.66
SCHEMBL1197102 0.66
SCHEMBL3465334 0.65 P2RX7 (0.32)
SCHEMBL3463922 0.62
SCHEMBL21737575 0.62 DYRK1A (0.48) DYRK1A
SCHEMBL20844009 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11759454-B2 Diazole lactams CHEMOCENTRYX, INC. (US) 2023-09-19 US disclosed
US-11759454-B2 Diazole lactams CHEMOCENTRYX, INC. (US) 2023-09-19 US disclosed
US-20210093613-A1 DIAZOLE LACTAMS CHEMOCENTRYX, INC. 2021-04-01 US disclosed
US-10744118-B2 Diazole lactams CHEMOCENTRYX, INC. (US) 2020-08-18 US disclosed
US-10744118-B2 Diazole lactams CHEMOCENTRYX, INC. (US) 2020-08-18 US disclosed
EP-2928474-B1 DIAZOLE LACTAMS CHEMOCENTRYX INC (US) 2018-11-14 EP disclosed
US-20160303084-A1 DIAZOLE LACTAMS CHEMOCENTRYX, INC. 2016-10-20 US disclosed
US-20160303084-A1 DIAZOLE LACTAMS CHEMOCENTRYX, INC. 2016-10-20 US disclosed
US-20160303084-A1 DIAZOLE LACTAMS CHEMOCENTRYX, INC. 2016-10-20 US disclosed
US-20160193191-A1 ANTAGONISTS OF CHEMOKINE RECEPTORS CHEMOCENTRYX, INC. 2016-07-07 US disclosed
CN-100542534-C Substituted piperazines CHEMOCENTRYX INC (US) 2009-09-23 CN disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 US disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 US disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 US disclosed
EP-1691810-A4 SUBSTITUTED PIPERAZINES CHEMOCENTRYX INC (US) 2009-07-01 EP disclosed
US-7435830-B2 Bicyclic and bridged nitrogen heterocycles CHEMOCENTRYX, INC. (US) 2008-10-14 US disclosed
EP-1691810-A1 SUBSTITUTED PIPERAZINES ChemoCentryx Inc (US) 2006-08-23 EP disclosed
US-20060106218-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2006-05-18 US disclosed
US-20050256130-A1 Substituted piperazines CHEMOCENTRYX, INC. (US) 2005-11-17 US disclosed
WO-2005056015-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160193191-A1 ANTAGONISTS OF CHEMOKINE RECEPTORS CCR1, CCR3, CCR2 HCAR2 35/4885DYRK1A 4220/4885
US-20160303084-A1 DIAZOLE LACTAMS CCR1, CCRL2, CCR4 HCAR2 153/4885DYRK1A 3929/4885
US-20210093613-A1 DIAZOLE LACTAMS CCR1, CCRL2, CCR4 HCAR2 153/4885DYRK1A 3929/4885
US-20060106218-A1 Substituted piperazines CCR1, CCR3, CCRL2 HCAR2 34/4885DYRK1A 4508/4885
US-20050256130-A1 Substituted piperazines CCR1, CCR3, CCRL2 HCAR2 34/4885DYRK1A 4508/4885
US-10744118-B2 Diazole lactams CCR1, CCRL2, CCR4 HCAR2 153/4885DYRK1A 3929/4885
US-11759454-B2 Diazole lactams CCR1, CCRL2, CCR4 HCAR2 153/4885DYRK1A 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.